7价与13价肺炎球菌结合疫苗在美国儿童中20年的公共卫生影响
该研究分析了美国2000年以来PCVs对5岁以下儿童侵袭性肺炎球菌疾病(IPD)的20年累计效果,通过主动细菌核心监测数据、文献复习和模型评估发现,PCVs避免了超过282,000例IPD,包括约16,000例脑膜炎、约172,000例菌血症和约55,000例菌血症性肺炎,并预防了大量中耳炎就诊、肺炎住院和死亡。
要点
- PCVs使用20年避免>282,000例儿童IPD,包括约16,000例脑膜炎。
- IPD病例从1997年15,707例降至2019年1,382例,下降91%。
- 中耳炎年均就诊率下降41%,肺炎住院下降66%-79%。
核心结论
- PCVs对美国5岁以下儿童IPD预防具有显著且持续的公共卫生效益。
研究设计与样本
- 基于主动细菌核心监测数据、文献复习及模型评估的20年累积效果分析。
主要发现
- PCVs避免>282,000例IPD,其中脑膜炎约16,000例、菌血症约172,000例、菌血症性肺炎约55,000例。
- IPD病例从1997年15,707例降至2019年1,382例,下降91%。
- 中耳炎年均就诊从PCV引入前78次/100儿童降至PCV13引入后46次/100儿童,下降41%。
- 肺炎年住院从1997年110,000-175,000例降至2019年37,000例,下降66%-79%。
临床怎么用
- 应继续维持并优化儿童PCV接种策略以巩固IPD防控效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pneumococcal conjugate vaccines (PCVs) have been used in the United States since 2000. To assess the cumulative 20-year effect of PCVs on invasive pneumococcal disease (IPD) incidence among children <5 years of age, we analyzed Active Bacterial Core Surveillance data, conducted a literature review, and modeled expected and observed disease. We found that PCVs have averted >282,000 cases of IPD, including ≈16,000 meningitis, ≈172,000 bacteremia, and ≈55,000 bacteremic pneumonia cases. In addition, vaccination has prevented 97 million healthcare visits for otitis media, 438,914-706,345 hospitalizations for pneumonia, and 2,780 total deaths. IPD cases declined 91%, from 15,707 in 1997 to 1,382 in 2019. Average annual visits for otitis media declined 41%, from 78 visits/100 children before PCV introduction to 46 visits/100 children after PCV13 introduction. Annual pneumonia hospitalizations declined 66%-79%, from 110,000-175,000 in 1997 to 37,000 in 2019. These findings confirm the substantial benefits of PCVs for preventing IPD in children.
引用
- Wasserman M, Chapman R, Lapidot R, et al. Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children. Emerg Infect Dis. 2021. PMID: 34013855. doi:10.3201/eid2706.204238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。